If You'd Invested $100 in CVS Health (CVS) Stock 5 Years Ago, Here's How Much You'd Have Today (Spoiler: You Wouldn't Have Lost Money)

Q4 revenue rose 8.2% YoY and full-year revenue increased 7.8%. However, CVS shares have materially underperformed the market (a $100 investment five years ago would be ~$108.11, a ~1.6% CAGR, vs ~$171.46 or ~11% CAGR for the S&P 500), as rising costs are compressing already-slim margins and Medicare Advantage rate increases look muted. The stock yields ~3.8% in dividends, but the Motley Fool Stock Advisor did not include CVS in its top-10 picks, suggesting there may be faster-growing or higher-yielding alternatives for portfolios.

Analysis

CVS's current weakness is a margin story wrapped in regulatory and pricing uncertainty — the immediate mechanism is compressed medical-loss economics inside Medicare Advantage and PBM spread pressure, which forces margin contraction faster than top-line churn. That dynamic amplifies second-order winners: lean national insurers with scale pricing power (who can flex network design) and outpatient/virtual-first care vendors that capture displaced utilization, while wholesalers and branded drug manufacturers face slower formulary adoption and delayed price pass-throughs.

Key catalysts cluster on a calendar: CMS MA guidance and actuarial rate finalization (next few months) and the next two CVS earnings cycles that will disclose Y/Y MLR and PBM spread trends. Tail risks include an adverse population‑health shock (respiratory season or pandemic resurgence) that balloons utilization within 60–90 days, and regulatory moves to claw back PBM revenues which would structurally reduce CVS’s PBM earnings over multiple years.

From a positioning standpoint, the cheapest way to express a near-term negative view is defined‑risk options; financing bearish exposure by monetizing elevated implied vol in healthcare defenders is efficient. Conversely, the market is also underweight the asymmetric optionality from CVS’s real‑estate and PBM scale — if MA pricing normalizes or PBM spreads widen, upside can be quick and >20% within 6–12 months, so total short exposure should be sized with a hard stop and a funding hedge.

The consensus is focused on near-term margin headlines and underweights the structural optionality in clinical and data franchises that can re‑rate multiples if management pivots to higher-margin care‑delivery initiatives. That makes a two‑legged approach — short tactical volatility, keep a small unlevered long for a multi‑quarter operational rebound — the most balanced way to profit from asymmetric outcomes.

Key Decisions for Investors

• Short CVS via a 6‑month bear put spread (buy 6‑month ~15% OTM put, sell 6‑month ~5% OTM put); target 12–20% downside in 3–6 months, max loss = premium paid (defined risk), reward ~3–5x premium if MA guidance misses expectations.
• Pair trade: Long NVDA Jan‑2027 LEAP calls (2x notional) funded ~50% by short CVS stock sized to net neutral beta exposure; time horizon 12–18 months. Rationale: capture asymmetric AI upside in NVDA while shorting a healthcare name exposed to policy/MLR shocks; size so NVDA upside >100% is a multi‑bagger but downside funded by short proceeds.
• Relative value: Buy a 9–12 month INTC call spread (bull call spread) to play semiconductor capital cycle re‑investment without outright long single‑stock gamma; limited premium, target 30–60% upside to spread if chip cycle re‑accelerates over 6–12 months.
• Income/defensive tactic on CVS: sell 30–90 day covered calls against existing CVS shares or new positions to harvest elevated time premium and dividends while maintaining downside protection; target 6–10% annualized carry, but trim on any >10% gap down.